The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

This discovery could have broad implications for how diseases like Alzheimer's and Parkinson's are approached ... of developing disease-modifying therapies that target microglia," said Majewska.

Lewy Body Diseases (including Parkinson's disease) and Multiple Sclerosis, in comparison to healthy controls. The findings reveal nine subpopulations, demonstrating that microglia exist under the ...

Researchers have identified that microglia first help spread Alzheimer’s disease pathology across the brain and then activate to limit its neurodegenerative effects. Researchers from the VIB-KU Leuven ...

“There must be other disease-modifying factors,” Tahirovic said. One such potential factor is the immune system, particularly microglia that respond to brain lesions and can ... where pathological ...

This discovery could have broad implications for how diseases like Alzheimer’s and Parkinson’s are approached ... of developing disease-modifying therapies that target microglia,” said ...

Our previous research demonstrates that the CD40 signaling is critically involved in microglia-related immune responses in the brain. For example, it is well known that the activation of the ...

“Normally, microglia are looking for things like viruses or injury and secreting substances that block off the damage,” Bernard explained. “In Parkinson’s disease, when they’re ...